BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 26886596)

  • 21. Regulation mechanism of Fbxw7-related signaling pathways (Review).
    Zhou Z; He C; Wang J
    Oncol Rep; 2015 Nov; 34(5):2215-24. PubMed ID: 26324296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The FBXW7 beta-form is suppressed in human glioma cells.
    Gu Z; Inomata K; Ishizawa K; Horii A
    Biochem Biophys Res Commun; 2007 Mar; 354(4):992-8. PubMed ID: 17274947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plk2 promotes tumor growth and inhibits apoptosis by targeting Fbxw7/Cyclin E in colorectal cancer.
    Ou B; Zhao J; Guan S; Wangpu X; Zhu C; Zong Y; Ma J; Sun J; Zheng M; Feng H; Lu A
    Cancer Lett; 2016 Oct; 380(2):457-466. PubMed ID: 27423313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of CDC4/FBXW7 in gastric carcinoma.
    Milne AN; Leguit R; Corver WE; Morsink FH; Polak M; de Leng WW; Carvalho R; Offerhaus GJ
    Cell Oncol; 2010; 32(5-6):347-59. PubMed ID: 20448329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer.
    Calcagno DQ; Freitas VM; Leal MF; de Souza CR; Demachki S; Montenegro R; Assumpção PP; Khayat AS; Smith Mde A; dos Santos AK; Burbano RR
    BMC Gastroenterol; 2013 Sep; 13():141. PubMed ID: 24053468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A widely used pan-isoform-FBXW7 antibody used in cell cycle studies does not detect FBXW7.
    Ennis H; McDonald DM
    Cell Cycle; 2023 Jun; 22(11):1380-1390. PubMed ID: 37183425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of FBXW7 in Gynecologic Malignancies.
    Di Fiore R; Suleiman S; Drago-Ferrante R; Subbannayya Y; Suleiman S; Vasileva-Slaveva M; Yordanov A; Pentimalli F; Giordano A; Calleja-Agius J
    Cells; 2023 May; 12(10):. PubMed ID: 37408248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coordination-driven FBXW7 DNAzyme-Fe nanoassembly enables a binary switch of breast cancer cell cycle checkpoint responses for enhanced ferroptosis-radiotherapy.
    Yu J; Zhang Y; Li L; Xiang Y; Yao X; Zhao Y; Cai K; Li M; Li Z; Luo Z
    Acta Biomater; 2023 Oct; 169():434-450. PubMed ID: 37516418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. F-box and WD repeat domain-containing 7 regulates intestinal cell lineage commitment and is a haploinsufficient tumor suppressor.
    Sancho R; Jandke A; Davis H; Diefenbacher ME; Tomlinson I; Behrens A
    Gastroenterology; 2010 Sep; 139(3):929-41. PubMed ID: 20638938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FBXW7 negatively regulates ENO1 expression and function in colorectal cancer.
    Zhan P; Wang Y; Zhao S; Liu C; Wang Y; Wen M; Mao JH; Wei G; Zhang P
    Lab Invest; 2015 Sep; 95(9):995-1004. PubMed ID: 26097998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell cycle-dependent degradation of the methyltransferase SETD3 attenuates cell proliferation and liver tumorigenesis.
    Cheng X; Hao Y; Shu W; Zhao M; Zhao C; Wu Y; Peng X; Yao P; Xiao D; Qing G; Pan Z; Yin L; Hu D; Du HN
    J Biol Chem; 2017 Jun; 292(22):9022-9033. PubMed ID: 28442573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor suppressor Fbxw7 antagonizes WNT signaling by targeting β-catenin for degradation in pancreatic cancer.
    Jiang JX; Sun CY; Tian S; Yu C; Chen MY; Zhang H
    Tumour Biol; 2016 Oct; 37(10):13893-13902. PubMed ID: 27485116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wnt/β-catenin signaling inhibits FBXW7 expression by upregulation of microRNA-770 in hepatocellular carcinoma.
    Wu WJ; Shi J; Hu G; Yu X; Lu H; Yang ML; Liu B; Wu ZX
    Tumour Biol; 2016 May; 37(5):6045-51. PubMed ID: 26602384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors.
    Kitade S; Onoyama I; Kobayashi H; Yagi H; Yoshida S; Kato M; Tsunematsu R; Asanoma K; Sonoda K; Wake N; Hata K; Nakayama KI; Kato K
    Cancer Sci; 2016 Oct; 107(10):1399-1405. PubMed ID: 27486687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis.
    Wang J; Wang H; Peters M; Ding N; Ribback S; Utpatel K; Cigliano A; Dombrowski F; Xu M; Chen X; Song X; Che L; Evert M; Cossu A; Gordan J; Zeng Y; Chen X; Calvisi DF
    J Hepatol; 2019 Oct; 71(4):742-752. PubMed ID: 31195063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-25 promotes gastric cancer proliferation, invasion, and migration by directly targeting F-box and WD-40 Domain Protein 7, FBXW7.
    Gong J; Cui Z; Li L; Ma Q; Wang Q; Gao Y; Sun H
    Tumour Biol; 2015 Sep; 36(10):7831-40. PubMed ID: 25944166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression.
    Lerner M; Lundgren J; Akhoondi S; Jahn A; Ng HF; Akbari Moqadam F; Oude Vrielink JA; Agami R; Den Boer ML; Grandér D; Sangfelt O
    Cell Cycle; 2011 Jul; 10(13):2172-83. PubMed ID: 21597324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.
    Akhoondi S; Lindström L; Widschwendter M; Corcoran M; Bergh J; Spruck C; Grandér D; Sangfelt O
    Breast Cancer Res; 2010; 12(6):R105. PubMed ID: 21122106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of mouse Fbxw7 isoforms is regulated in a cell cycle- or p53-dependent manner.
    Matsumoto A; Onoyama I; Nakayama KI
    Biochem Biophys Res Commun; 2006 Nov; 350(1):114-9. PubMed ID: 16989775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiR-25 is up-regulated in non-small cell lung cancer and promotes cell proliferation and motility by targeting FBXW7.
    Xiang J; Hang JB; Che JM; Li HC
    Int J Clin Exp Pathol; 2015; 8(8):9147-53. PubMed ID: 26464659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.